Search results
Results from the WOW.Com Content Network
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia.It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired ...
On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, [24] as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. [25] Metraleptin was originally developed at Amylin Pharmaceuticals. [26]
If symptoms persist, metreleptin can be prescribed. Metreleptin (MYALEPT) is a recombinant human leptin analog and was approved by FDA in 2014 for generalized lipodystrophy as an adjunct therapy to diet to treat the complication of leptin deficiency. [14]
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy ...
Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month ...
It appears February is going to end with a bang for the Food and Drug Administration, which, barring another major winter snowstorm, will rule on two drugs next week. Let's have a closer look at ...
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD). [6] Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha ...
The U.S. Food and Drug Administration (FDA) approved the drug for use in acute pain, but Vertex aims to eventually win approval in chronic pain, too. Clinical trials are ongoing, ...